Although the mechanism by which GVHD depletes LGR5+ HFSCs and CK15+ RLP stem cells remains to be clarified, it is worth of note that topical administration of ruxolitinib protects these stem cells from mouse GVHD (19). This evidence concerns the gene LGR5 and graft versus host disease.